Editing of highly homologous gamma-globin genes by nickase deficient Base Editor mitigates large intergenic deletions
George, A.; Ravi, N. S.; Babu, V.; Marepally, S.; Thangavel, S.; Velayudhan, S. R.; Srivastava, A.; Mohankumar, K. M.
Show abstract
Base editing in gamma-globin promoter is a promising approach for reactivation of fetal-hemoglobin. Recent studies have shown that base editing could result in genotoxic events at the gamma globin locus including 4.9 kb large deletion of intervening region due to nicking in the paralogous HBG1 and HBG2 genes. Although the deletion frequency is less than what is observed with Cas9, it could diminish the therapeutic potential. We sought to evaluate if large deletion could be overcome while maintaining the editing efficiency by replacing the nCas9 of ABE8e with a catalytically inactive deadCas9 (dCas9). Using 3 therapeutically relevant gRNAs targeting the gamma globin promoter, we performed a comprehensive evaluation of the editing outcome and frequency of large deletion using dCas9, nCas9, dCas9-ABE8e and nCas9-ABE8e. Our findings indicate that while nicking in itself induced large deletions, the frequency reduced upon efficient base editing. Notably, there was no appreciable deletion with the use of dCas9-ABE8e making it a safer approach, in terms of genome integrity, for therapeutic genome editing in the gamma-globin locus. Further, we also demonstrate that dCas9 ABE8e can edit efficiently in primary human CD34+ hematopoietic stem and progenitor cells (HSPCs) to achieve therapeutic benefits.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A prime editing strategy to rewrite the γ-globin promoters and reactivate fetal hemoglobin for sickle cell disease 93%
- Mutant-SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms 92%
- Hematopoietic recovery after transplantation is primarily derived from the stochastic contribution of hematopoietic stem cells 91%
Similar papers in this journal
- Clinically Relevant Gene Editing in Hematopoietic Stem Cells for the Treatment of Pyruvate Kinase Deficiency Hemolytic Anemia 95%
- In vitro and In vivo Genetic Disease Modelling via NHEJ precise deletions using CRISPR/Cas9 94%
- Sort-purification of human CD34+CD90+ cells reduces target cell population and improves lentiviral transduction 92%
Similar papers in this journal
- Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of β-hemoglobinopathies 95%
- Multiplex HDR for Disease and Correction Modeling of SCID by CRISPR Genome Editing in Human HSPCs 93%
- Allele-specific CRISPR/Cas9 editing inactivates a single nucleotide variant associated with collagen VI muscular dystrophy 90%
Similar papers in this journal
Similar papers in this journal
- Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell disease 94%
- Safety and efficacy study of CRISPR/Cas9 treatment of sickle cell disease in clinically relevant conditions highlights disease-specific response 94%
- TALEN-mediated intron editing of HSPCs enables transgene expression restricted to the myeloid lineage 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.